Summary & Overview
HCPCS J3393: Injection of betibeglogene autotemcel, per treatment
HCPCS Level II code J3393 denotes the per-treatment injection of betibeglogene autotemcel, a gene therapy biologic used in specialized clinical settings. As a high-cost, single-treatment or limited-course injectable, this code is significant for national coverage policy, prior authorization workflows, and site-of-service billing. It is relevant to hospital outpatient departments and dedicated infusion or gene therapy administration centers.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used in billing, payer coverage patterns, and the clinical service context for administration. The publication summarizes benchmark considerations, commonly reported modifiers and service-line implications, and highlights areas where policy updates or payer-specific rules commonly arise.
This overview provides clinicians, coding professionals, and policy analysts with the coding description, expected sites of service, and the payer landscape to inform billing preparation and administrative planning. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J3393 describes an injection of betibeglogene autotemcel, per treatment. This code represents administration of a gene therapy product intended as a one-time or per-treatment injectable biologic.
-
Service type: Injectable biologic/gene therapy administration
-
Typical site of service: Hospital outpatient department or specialized infusion/administration center
Clinical & Coding Specifications
Clinical Context
A 9-year-old child with transfusion-dependent beta-thalassemia is evaluated in a tertiary pediatric hematology center for gene therapy using betibeglogene autotemcel. The clinical workflow begins with multidisciplinary evaluation including hematology, transplant specialists, genetics, and infectious disease. Pre-treatment workup includes confirmatory genotyping, organ function testing, infectious disease screening, and assessment for eligibility. Following conditioning chemotherapy and stem cell mobilization as per protocol, the patient receives a single administration of J3393 (betibeglogene autotemcel) as an intravenous cellular therapy infusion in an inpatient or specialized outpatient infusion center equipped for cellular therapies. Post-infusion monitoring includes inpatient observation for immediate infusion reactions, routine labs to monitor hematologic recovery, infection surveillance, and longer-term routine follow-up visits with performance status and hemoglobin/iron assessments. Supportive services such as blood bank, pharmacy (handling cellular product thawing and preparation), and intensive care backup are typically available during the peri-infusion period.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no modifier applies |